4Tissue raises €7 million in Series A financing and appoints Stéphanie Dupont as CEO
Ghent, 20 October 2026 — 4Tissue, a Belgian medtech company developing solutions for regenerative medicine, announces the successful closing of a €7 million Series A financing round and the appointment of Stéphanie Dupont as Chief Executive Officer (CEO). The financing and leadership appointment mark an important new phase in 4Tissue's development, supporting the company's continued clinical advancement and growth.
The financing will support 4Tissue's next phase of development, focusing on its first-in-human (FIH) study, manufacturing scale-up and further development of its technology platform for additional applications in regenerative medicine.
4Tissue is developing a bioresorbable, injectable hydrogel designed to support natural tissue regeneration. The technology is being developed for breast reconstruction and augmentation, with the aim of providing a less invasive, patient-friendly alternative to existing techniques. The platform also holds potential for other applications where soft tissue repair and regeneration represent an important clinical need.
Stéphanie Dupont appointed CEO
Alongside the financing round, 4Tissue announces the appointment of Stéphanie Dupont as CEO. Stéphanie brings more than 15 years of experience advancing innovative technologies from development through commercialization. She has held leadership positions at Barco, miDiagnostics, Talis Biomedical, HP and Bain & Company, leading international teams across product management, marketing and R&D.
She holds a PhD in Materials Science & Engineering from Stanford University, combining a strong scientific and technical background with experience in product strategy and bringing innovative technologies to market. This combination of expertise closely aligns with 4Tissue's next phase of development.
"4Tissue is at an important inflection point," said Stéphanie Dupont, CEO of 4Tissue. "As we move towards our first clinical study, we are getting closer to our goal of making our technology available to patients. The combination of strong science, a clear clinical need and the potential to make a tangible difference for patients makes this an exciting phase. I look forward to working with the team, our investors and partners to shape the company's next phase of growth."
Dr. Katleen Verleysen, Chair of the Board of Directors of 4Tissue, welcomed the appointment:
"Stéphanie brings the combination of scientific expertise, product strategy and international experience that 4Tissue needs at this stage. Her experience in advancing innovative technologies from development through commercialization will be particularly valuable as we move towards clinical application. Together with our team and the new financing, we have a solid foundation to achieve our next clinical and operational milestones."
Virginie Saverys, investor, added:
"4Tissue has developed an innovative technology that addresses a significant unmet clinical need. We strongly believe in the potential of the platform, the team and the company's strategy, and look forward to supporting 4Tissue through this next phase of development."
The successful Series A financing builds on 4Tissue's previous funding and underscores investors' confidence in the company's technology and strategy. With €7 million in new funding, a strengthened leadership team and a clear clinical development pathway, 4Tissue is well positioned to achieve important clinical and operational milestones in the coming years and further strengthen its position in regenerative medicine.
About 4Tissue
4Tissue is a Belgian medtech company developing innovative solutions for tissue regeneration and regenerative medicine. The company is developing a bioresorbable, injectable hydrogel designed to support the body's natural regenerative processes. Its initial application focuses on breast reconstruction and augmentation, aiming to provide women following breast cancer with a less invasive, patient-friendly reconstructive solution. In the longer term, 4Tissue aims to leverage its technology platform across multiple applications in soft tissue regeneration.
For more information, visit www.4tissue.com.
Media contact:
Stéphanie Dupont
CEO
info@4tissue.com
